表紙:抗凝固剤市場:世界の業界動向、シェア、規模、成長、機会、予測(2022年~2027年)
市場調査レポート
商品コード
1091938

抗凝固剤市場:世界の業界動向、シェア、規模、成長、機会、予測(2022年~2027年)

Anticoagulants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 145 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.18円
抗凝固剤市場:世界の業界動向、シェア、規模、成長、機会、予測(2022年~2027年)
出版日: 2022年06月13日
発行: IMARC Services Private Limited
ページ情報: 英文 145 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗凝固剤の市場規模は、2021年に340億米ドルとなりました。同市場は今後、2022年~2027年の間に10.2%のCAGRで拡大し、2027年には608億米ドルに達すると予測されています。

当レポートでは、世界の抗凝固剤市場について調査し、市場の概要とともに、薬剤クラス別、投与経路別、流通チャネル別、用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の抗凝固剤市場

  • 市場概要
  • 市場実績
  • COVID-19の影響

第6章 市場の内訳、薬剤クラス別

  • 新規経口抗凝固薬(NOAC)
  • ヘパリンと低分子量ヘパリン(LMWH)
  • ビタミンK拮抗薬
  • その他

第7章 市場の内訳、投与経路別

  • 経口
  • 注射

第8章 市場の内訳、流通チャネル別

  • 院内薬局
  • 小売薬局
  • オンラインストア
  • その他

第9章 市場の内訳、用途別

  • 心房細動と心臓発作
  • 脳卒中
  • 深部静脈血栓症(DVT)
  • 肺塞栓症(PE)
  • その他

第10章 市場の内訳、地域別

  • 北米
  • アジア太平洋
  • 欧州
  • ラテンアメリカ
  • 中東・アフリカ

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Alexion Pharmaceuticals Inc
    • Aspen Holdings
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • Dr. Reddy's Laboratories Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson Private Limited
    • Pfizer Inc.
    • Sanofi
図表

List of Figures

  • Figure 1: Global: Anticoagulants Market: Major Drivers and Challenges
  • Figure 2: Global: Anticoagulants Market: Sales Value (in Billion US$), 2016-2021
  • Figure 3: Global: Anticoagulants Market Forecast: Sales Value (in Billion US$), 2022-2027
  • Figure 4: Global: Anticoagulants Market: Breakup by Drug Class (in %), 2021
  • Figure 5: Global: Anticoagulants Market: Breakup by Route of Administration (in %), 2021
  • Figure 6: Global: Anticoagulants Market: Breakup by Distribution Channel (in %), 2021
  • Figure 7: Global: Anticoagulants Market: Breakup by Application (in %), 2021
  • Figure 8: Global: Anticoagulants Market: Breakup by Region (in %), 2021
  • Figure 9: Global: Anticoagulants (Novel Oral Anticoagulants-NOACs) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 10: Global: Anticoagulants (Novel Oral Anticoagulants-NOACs) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 11: Global: Anticoagulants (Heparin and Low Molecular Weight Heparin-LMWH) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 12: Global: Anticoagulants (Heparin and Low Molecular Weight Heparin-LMWH) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 13: Global: Anticoagulants (Vitamin K Antagonist) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 14: Global: Anticoagulants (Vitamin K Antagonist) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 15: Global: Anticoagulants (Other Drug Classes) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 16: Global: Anticoagulants (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 17: Global: Anticoagulants (Oral Anticoagulant) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 18: Global: Anticoagulants (Oral Anticoagulant) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 19: Global: Anticoagulants (Injectable Anticoagulant) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 20: Global: Anticoagulants (Injectable Anticoagulant) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 21: Global: Anticoagulants (Hospital Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 22: Global: Anticoagulants (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 23: Global: Anticoagulants (Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 24: Global: Anticoagulants (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 25: Global: Anticoagulants (Online Stores) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 26: Global: Anticoagulants (Online Stores) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 27: Global: Anticoagulants (Other Distribution Channels) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 28: Global: Anticoagulants (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 29: Global: Anticoagulants (Atrial Fibrillation and Heart Attack) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 30: Global: Anticoagulants (Atrial Fibrillation and Heart Attack) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 31: Global: Anticoagulants (Stroke) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 32: Global: Anticoagulants (Stroke) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 33: Global: Anticoagulants (Deep Vein Thrombosis-DVT) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 34: Global: Anticoagulants (Deep Vein Thrombosis-DVT) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 35: Global: Anticoagulants (Pulmonary Embolism-PE) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 36: Global: Anticoagulants (Pulmonary Embolism-PE) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 37: Global: Anticoagulants (Other Applications) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 38: Global: Anticoagulants (Other Applications) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 39: North America: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 40: North America: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 41: United States: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 42: United States: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 43: Canada: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 44: Canada: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 45: Asia-Pacific: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 46: Asia-Pacific: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 47: China: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 48: China: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 49: Japan: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 50: Japan: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 51: India: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 52: India: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 53: South Korea: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 54: South Korea: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 55: Australia: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 56: Australia: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 57: Indonesia: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 58: Indonesia: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 59: Others: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 60: Others: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 61: Europe: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 62: Europe: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 63: Germany: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 64: Germany: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 65: France: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 66: France: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 67: United Kingdom: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 68: United Kingdom: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 69: Italy: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 70: Italy: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 71: Spain: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 72: Spain: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 73: Russia: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 74: Russia: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 75: Others: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 76: Others: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 77: Latin America: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 78: Latin America: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 79: Brazil: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 80: Brazil: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 81: Mexico: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 82: Mexico: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 83: Others: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 84: Others: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 85: Middle East and Africa: Anticoagulants Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 86: Middle East and Africa: Anticoagulants Market: Breakup by Country (in %), 2021
  • Figure 87: Middle East and Africa: Anticoagulants Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 88: Global: Anticoagulants Industry: SWOT Analysis
  • Figure 89: Global: Anticoagulants Industry: Value Chain Analysis
  • Figure 90: Global: Anticoagulants Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anticoagulants Market: Key Industry Highlights, 2021 and 2027
  • Table 2: Global: Anticoagulants Market Forecast: Breakup by Drug Class (in Million US$), 2022-2027
  • Table 3: Global: Anticoagulants Market Forecast: Breakup by Route of Administration (in Million US$), 2022-2027
  • Table 4: Global: Anticoagulants Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
  • Table 5: Global: Anticoagulants Market Forecast: Breakup by Application (in Million US$), 2022-2027
  • Table 6: Global: Anticoagulants Market Forecast: Breakup by Region (in Million US$), 2022-2027
  • Table 7: Global: Anticoagulants Market: Competitive Structure
  • Table 8: Global: Anticoagulants Market: Key Players
目次
Product Code: SR0622A64_Report

The global anticoagulants market reached a value of US$ 34.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 60.8 Billion by 2027, exhibiting a CAGR of 10.2% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Blood clots form when blood thickens and forms a semi-solid mass in any part of the body. This causes serious problems, such as stroke, heart attack, pulmonary embolism, transient ischemic attacks, and deep vein thrombosis (DVT). As a result, doctors around the world are prescribing anticoagulant drugs to people who are at a high risk of clot formation. These drugs help in thinning blood, preventing or reducing blood clotting, and prolonging the clotting time. They are usually available in capsule or tablet form, including warfarin, rivaroxaban, dabigatran and apixaban.

Anticoagulants Market Trends:

Recent research indicates that hypercoagulability in individuals affected by the coronavirus disease (COVID-19) pandemic can be one of the leading causes of mortality worldwide. As a result, its surging cases are positively influencing the demand for anticoagulant drugs to treat the thrombotic condition among critically ill or hospitalized patients. Moreover, certain risk factors, such as extended sitting, smoking, trauma, blood disorders, and autoimmune diseases, can cause blood clotting in different parts of the body. This, in confluence with the increasing prevalence of human immunodeficiency virus (HIV), hepatitis C, Lyme disease, obesity, cancer, and chronic inflammation, represents another significant factor strengthening the growth of the market. Apart from this, the growing aging population across the globe is resulting in the escalating demand for surgical services. Surgeries often require prolonged bed rest, which, in turn, increases the risk of blood clotting and the overall sales of anticoagulant drugs. Furthermore, the improving diagnosis rates and the escalating demand for target therapeutics are fueling the market growth. The emergence of online pharmacies is also driving the demand for anticoagulant drugs around the world.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global anticoagulants market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class, route of administration, distribution channel and application.

Breakup by Drug Class:

  • Novel Oral Anticoagulants (NOACs)
  • Heparin and Low Molecular Weight Heparin (LMWH)
  • Vitamin K Antagonist
  • Others

Breakup by Route of Administration:

  • Oral Anticoagulant
  • Injectable Anticoagulant

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Others

Breakup by Application:

  • Atrial Fibrillation and Heart Attack
  • Stroke
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Alexion Pharmaceuticals Inc, Aspen Holdings, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddy's Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Pfizer Inc. and Sanofi.

Key Questions Answered in This Report:

  • How has the global anticoagulants market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global anticoagulants market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global anticoagulants market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anticoagulants Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Novel Oral Anticoagulants (NOACs)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Heparin and Low Molecular Weight Heparin (LMWH)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Vitamin K Antagonist
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral Anticoagulant
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable Anticoagulant
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Atrial Fibrillation and Heart Attack
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Stroke
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Deep Vein Thrombosis (DVT)
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Pulmonary Embolism (PE)
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Alexion Pharmaceuticals Inc
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Aspen Holdings
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bayer AG
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Boehringer Ingelheim International GmbH
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Bristol-Myers Squibb Company
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Daiichi Sankyo Company Limited
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Dr. Reddy's Laboratories Ltd
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 GlaxoSmithKline plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Johnson & Johnson Private Limited
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sanofi
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis